Tests CC-92480 combinations in adults with relapsed or refractory multiple myeloma
Tests CC-92480 with other drugs in adults with returning or resistant multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Badalona, Madrid, and Santander, SpainSee the 3 sites
- Phase
- Phase 1/2
Where in Spain
- Institut Catala d'OncologiaBadalona, SpainNo longer taking part
- Hospital Universitario 12 de OctubreMadrid, SpainNo longer taking part
- Hospital Universitario Marqués de ValdecillaSantander, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT05372354EU 2023-509384-25-00
- Record updated
- 5 September 2025
- Original description
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).Read full original descriptionShow less
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Inclusion: Relapsed or refractory multiple myeloma (MM) and must:; Have documented disease progression during or after their last myeloma therapy; For Part 1 Dose Finding: Be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit in MM; For Part 2 Dose Expansion: Be refractory to or have relapsed after the protocol specified number of prior lines of therapy that include an immunomodulatory drug (IMiD), a proteasome inhibitor, an anti-CD38 mAb, and a T-cell redirecting therapy (TRT, eg, a CAR-T or T-cell engaging bispecific treatment) unless the participant is not a candidate for TRT; Must have measurable disease; Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1; Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP).
Exclusion: Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptomatic infections or 28 days for severe/critical illness prior to Cycle 1 Day 1 (C1D1); For Part 1: received prior therapy with CC-92480; For Part 2: received prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib; Previously received allogeneic stem-cell transplant at any time or received autologous stem-cell transplant within 12 weeks of initiating study treatment; Received any of the following within 14 days prior to initiating study treatment:; Plasmapheresis; Major surgery; Radiation therapy other than local therapy for myeloma associated bone lesions; Use of any systemic anti-myeloma drug therapy; Used any investigational agents within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment; COVID-19 vaccine within 14 days prior to C1D1; Other protocol-defined inclusion/exclusion criteria apply; Known active or history of central nervous system (CNS) involvement of MM; Plasma cell leukemia; Waldenstrom's macroglobulinemia; polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; or clinically significant light-chain amyloidosis; Impaired cardiac function or clinically significant cardiac disease.